Journal Article Epublish 4 citations
PubMed: 38473829 DOI: 10.3390/ijms25052583
The Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac.
Int J Mol Sci 25(5)
Authors: Ho-Yu Ng, Yunshi Liao, Ruiqi Zhang, Kwok-Hung Chan, Wai-Pan To, Chun-Him Hui, Wai-Kay Seto, Wai K Leung, Ivan F N Hung, Tommy T Y Lam, Ka-Shing Cheung
Affiliations
- School of Clinical Medicine, The University of Hong Kong, Hong Kong.
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
- Department of Microbiology, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
- State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong. Centre for Immunology & Infection Ltd. 17W Hong Kong Science & Technology Parks, Hong Kong. Laboratory of Data Discovery for Health Ltd. 19W Hong Kong Science & Technology Parks, Hong Kong. School of Public Health, The University of Hong Kong, Hong Kong.
Abstract
CoronaVac immunogenicity decreases with time, and we aimed to investigate whether gut microbiota associate with longer-term immunogenicity of CoronaVac. This was a prospective cohort study recruiting two-dose CoronaVac recipients from three centres in Hong Kong. We collected blood samples at baseline and day 180 after the first dose and used chemiluminescence immunoassay to test for neutralizing antibodies (NAbs) against the receptor-binding domain (RBD) of wild-type SARS-CoV-2 virus. We performed shotgun metagenomic sequencing performed on baseline stool samples. The primary outcome was the NAb seroconversion rate (seropositivity defined as NAb ≥ 15AU/mL) at day 180. Linear discriminant analysis [LDA] effect size analysis was used to identify putative bacterial species and metabolic pathways. A univariate logistic regression model was used to derive the odds ratio (OR) of seropositivity with bacterial species. Of 119 CoronaVac recipients (median age: 53.4 years [IQR: 47.8-61.3]; male: 39 [32.8%]), only 8 (6.7%) remained seropositive at 6 months after vaccination. (logLDA score = 4.39) and (logLDA score = 3.89) were significantly enriched in seropositive than seronegative participants. Seropositivity was associated with (OR: 5.73; 95% CI: 1.32-29.55; = 0.022) and with borderline significance (OR: 3.27; 95% CI: 0.73-14.72; = 0.110). Additionally, was positively correlated with most enriched metabolic pathways in seropositive vaccinees, including the superpathway of adenosine nucleotide de novo biosynthesis I (logLDA score = 2.88) and II (logLDA score = 2.91), as well as pathways related to vitamin B biosynthesis, all of which are known to promote immune functions. In conclusion, certain gut bacterial species ( and ) and metabolic pathways were associated with longer-term CoronaVac immunogenicity.
MeSH
Sars-Cov-2, Vaccines, Immunogenicity, Vaccine, Predictive Value Of Tests, Gastrointestinal Microbiome, Microbiota